Department of Pathology and Laboratory Medicine, Dartmouth-Hitchcock Medical Center, Lebanon, NH and Geisel School of Medicine at Dartmouth, Hanover, New Hampshire, USA.
Department of Surgery, Dartmouth-Hitchcock Medical Center and Geisel School of Medicine at Dartmouth, Lebanon, New Hampshire, USA.
J Cutan Pathol. 2020 Oct;47(10):934-945. doi: 10.1111/cup.13728. Epub 2020 Jul 29.
Ossifying fibromyxoid tumor (OFMT) is a rare soft tissue neoplasm of uncertain differentiation and intermediate biologic potential. Up to 85% of OFMTs, including benign, atypical, and malignant forms, harbor fusion genes. Most commonly, the PHF1 gene localized to 6p21 is fused with EP400, but other fusion partners, such as MEAF6, EPC1, and JAZF1 have also been described. Herein, we present two rare cases of superficial OFMTs with ZC3H7B-BCOR and the very recently described PHF1-TFE3 fusions. The latter also exhibited moderate to strong diffuse immunoreactivity for TFE3. Reciprocally, this finding expands the entities with TFE3 rearrangements. Accumulation of additional data is necessary to determine if OFMTs harboring these rare fusions feature any reproducible clinicopathologic findings or carry prognostic and/or predictive implications.
骨化性纤维黏液样肿瘤(OFMT)是一种罕见的软组织肿瘤,其分化程度不确定,生物学潜能为中度。多达 85%的 OFMT,包括良性、非典型和恶性形式,都存在融合基因。最常见的是,定位于 6p21 的 PHF1 基因与 EP400 融合,但也已经描述了其他融合伙伴,如 MEAF6、EPC1 和 JAZF1。在此,我们介绍了两个罕见的浅表 OFMT 病例,其存在 ZC3H7B-BCOR 和最近描述的 PHF1-TFE3 融合。后者还表现出 TFE3 的中度至强弥漫免疫反应性。反过来,这一发现扩大了 TFE3 重排的实体范围。需要积累更多的数据来确定是否携带这些罕见融合的 OFMT 是否具有任何可重复的临床病理发现,或者是否具有预后和/或预测意义。